



## **F-star Therapeutics to Participate in the BTIG Targeted Therapeutics Conference**

**Cambridge, UK and Cambridge, MA, February 20, 2020** – F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb<sup>2™</sup>) antibodies, today announced that Dr. Louis Kayitalire, Chief Medical Officer, will participate in a panel discussion at the BTIG Targeted Therapeutics Conference on Monday, 24 February 2020 in New York, NY.

Dr. Kayitalire will take part in a panel titled “*Next Steps in IO: Material Happenings in Melanoma and More*”, which will be taking place from 3:00pm–4:00pm at the St. Regis, New York, NY.

The company will also be available for one on one meetings during the conference.

### **About F-star Therapeutics Ltd**

F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb<sup>2™</sup>) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for patients with cancer. For more information visit [www.f-star.com](http://www.f-star.com).

- END-

### **For further information, please contact:**

#### **For investor enquiries**

**Lindsey Trickett**

VP Investor Relations & Communications

+1 240 543 7970

[lindsey.trickett@f-star.com](mailto:lindsey.trickett@f-star.com)

#### **For media enquiries**

**Consilium Strategic Communications**

Chris Gardner, Sue Stuart, David Daley

Tel: +44 (0)20 3709 5700

E-mail: [F-star@consilium-comms.com](mailto:F-star@consilium-comms.com)